CIDARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.63 USD | -2.85% |
|
-7.27% | -20.47% |
| 25/04 | Top Premarket Gainers | MT |
| 25/04 | North American Morning Briefing : More Tech -2- | DJ |
Chart calendar Cidara Therapeutics, Inc.
3535ec7c631f2f04f03502ee9b679._FF0xgjLcIilACmwfsBfctjeiHkZn_5xBvmf8SYhynk.vishrXq4AN_Ia0jdCoonRqCB4TRTspIuM5vJhG5b-wPNKxDxT5My-OhMHQ~e8ecdd7333ac1ae3417cefad4bba5699
Upcoming events on Cidara Therapeutics, Inc.
Past events on Cidara Therapeutics, Inc.
| 25/04/2024 02:00 am | Business Update Call |
| 23/04/2024 02:40 am | Q4 2023 Earnings Release |
| 09/04/2024 02:00 am | American Association for Cancer Research Meeting - Simon Döhrmann |
| 09/04/2024 02:00 am | American Association for Cancer Research Meeting - Amanda Almaguer |
| 09/04/2024 02:00 am | American Association for Cancer Research Meeting - James Levin |
| 08/04/2024 09:30 pm | American Association for Cancer Research Meeting - Elizabeth Abelovski |
| 04/04/2024 08:30 pm | Extraordinary Shareholders Meeting |
| 28/02/2024 | Q4 2023 Earnings Release (Projected) |
| 07/12/2023 04:30 pm | European Society for Medical Oncology Immuno Oncology Congress - Discovery of a Novel, Dual CD73 & P |
| 07/12/2023 04:30 pm | European Society for Medical Oncology Immuno Oncology Congress - Discovery of CBO421, a First-in-Cla |
| 04/11/2023 12:30 am | Society for Immunotherapy of Cancer Meeting |
| 03/11/2023 01:45 am | Q3 2023 Earnings Release |
| 14/10/2023 09:45 pm | IDWeek Conference - James Levin |
| 14/10/2023 09:45 pm | IDWeek Conference - Shawn Flanagan |
| 14/10/2023 08:00 pm | IDWeek Conference - James Levin |
| 21/09/2023 09:30 pm | R&D Day |
| 11/09/2023 07:30 pm | H.C. Wainwright Global Investment Conference |
| 04/08/2023 01:38 am | Q2 2023 Earnings Release |
| 22/06/2023 08:30 pm | Annual General Meeting |
| 22/06/2023 07:00 pm | Adenosine Pathway Targeted Cancer Immunotherapy Summit |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 20,9 17,1 22.67% | 12,1 18,5 -34.89% | 49,6 46,6 6.28% | 64,3 64,7 -0.62% | 63,9 57,8 10.47% | 24,1 |
|
EBITDA | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -41,7 -47,4 11.9% | -71,8 -60,9 -17.92% | -42,3 -47,1 10.21% | -29,7 -28,4 -4.82% | -24,5 -28,1 12.97% | -63,1 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -41,1 -41,9 2.04% | -72,1 -61,1 -18.06% | -42,5 -47,5 10.66% | -29,5 -28,3 -4.37% | -22,5 -26,3 14.63% | -61,8 |
|
Net income Million USD | Released Forecast Spread | -41,1 -42,1 2.42% | -74,9 -62,4 -19.9% | -42,5 -47,9 11.39% | -29,8 -30,4 1.82% | -22,9 -27,4 16.29% | -61,8 |
|
EPS USD | Released Forecast Spread | -28,2 -27,7 -1.84% | -36,0 -30,9 -16.5% | -16,2 -17,7 8.3% | -8,60 -8,33 -3.2% | -5,20 -6,13 15.22% | -12,9 |
| Announcement Date | 04/03/20 | 25/02/21 | 07/03/22 | 23/03/23 | 22/04/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 7,23 4,31 67.62% | 7,11 4,71 50.86% | 6,22 4,97 25.2% | 40,7 22,7 79.67% | 10,2 10,6 -3.29% | 26,0 18,7 39.11% | 7,61 11,5 -34.06% | 12,7 8,14 56.25% | 17,6 11,5 52.34% | 9,03 | 4,23 | 5,33 | 6,34 |
|
EBIT Million USD | Released Forecast Spread | -16,8 -21,6 22.25% | -18,3 -19,2 4.75% | -13,1 -19,3 32.06% | 14,9 5,83 156.13% | -13,3 -11,9 -11.49% | 2,98 -3,28 190.67% | -12,8 -12,4 -3.31% | -8,56 -15,2 43.68% | -3,68 -9,86 62.71% | -11,3 | -16,0 | -17,2 | -17,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -16,8 -21,6 22.06% | -18,3 -19,2 4.83% | -13,1 -19,2 31.73% | 15,0 5,81 157.63% | -13,1 -11,9 -10.28% | 3,21 -3,13 202.42% | -12,2 -12,3 0.51% | -7,94 -13,6 41.51% | -3,15 -9,53 66.94% | -11,0 | -15,7 | -16,9 | -17,4 |
|
Net income Million USD | Released Forecast Spread | -16,8 -21,6 22.06% | -18,3 -19,2 4.83% | -13,1 -19,3 32.18% | 11,9 5,81 104.64% | -13,4 -11,9 -12.57% | 2,53 -3,13 180.81% | -12,4 -12,3 -0.71% | -8,17 -13,6 39.81% | -3,21 -9,53 66.27% | -11,0 | -15,7 | -16,9 | -17,4 |
|
EPS USD | Released Forecast Spread | -5,60 -6,50 13.85% | -5,40 -5,56 2.88% | -3,80 -5,60 32.14% | 3,40 1,35 151.85% | -3,80 -2,93 -29.55% | 0,60 -0,73 181.82% | -2,80 -2,60 -7.69% | -1,80 -3,00 40% | -0,80 -2,07 61.29% | -2,39 | -3,36 | -3,65 | -3,30 |
| Announcement Date | 07/03/22 | 11/05/22 | 09/08/22 | 03/11/22 | 23/03/23 | 11/05/23 | 03/08/23 | 02/11/23 | 22/04/24 | - | - | - | - |
More events
Past sector events for Cidara Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CDTX Stock
- Calendar Cidara Therapeutics, Inc.
